Back to discover
Drug

liposomal amphotericin B

In clinical development
Emerging researchLate-stage development
Also known as AMPHOTERICIN B LIPOSOME, AmBisome, Amphotericin B, Amphotericin B Liposomal+1 more

AMPHOTERICIN B LIPOSOME, AmBisome, Amphotericin B, Amphotericin B Liposomal, amphotericin liposomal.

RxNorm236594
1
Research papers
4
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Clinical trial2026-04-23Results expected Q3 2030 · ClinicalTrials.gov

A Multi-Arm, Multi-Stage Randomized Controlled Clinical Trial Evaluating Systemic Therapeutic Regimens for the Treatment of Cutaneous Leishmaniasis in Ethiopia

Clinical trial2026-03-10Results expected Q1 2029 · ClinicalTrials.gov

A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis

Clinical trial2026-02-01Completed · ClinicalTrials.gov

Liposomal Amphotericin B in Patients With Invasive Aspergillosis and Hepatic Dysfunction: A Prospective Study

Clinical trial2026-01-13Results expected Q4 2026 · ClinicalTrials.gov

Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis

Clinical trial2025-07-10Primary completion · ClinicalTrials.gov

Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly

Clinical trial2024-06-01Primary completion · ClinicalTrials.gov

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Clinical trial2023-10-16Results posted · ClinicalTrials.gov

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly: a Randomized Clinical Trial

Clinical trial2023-09-01Completed · ClinicalTrials.gov

Phase I, Prospective, Randomised, Controlled Study on the Safety and Efficacy of Nebulised Liposomal Amphotericin as an Adjuvant Treatment for Invasive Pulmonary Aspergillosis

Clinical trial2022-11-10Completed · ClinicalTrials.gov

A Randomized Controlled Trial of Combined Inhalational With Intravenous Amphotericin B in Comparison With Intravenous Amphotericin B Alone for Treatment of Pulmonary Mucormycosis

Clinical trial2021-12-30Completed · ClinicalTrials.gov

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

Research2020-12-14The Lancet. Infectious diseases

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)

Clinical trial2019-06-28Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
liposomal amphotericin B
Aliases & brands
AMPHOTERICIN B LIPOSOMEAmBisomeAmphotericin BAmphotericin B Liposomalamphotericin liposomal
RxNorm CUI
236594

Clinical trials

37 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
37
registered trials across all phases
LATEST COMPLETION 2026
4
Active studies
4
Recruiting
23
Late-stage (III+)
24
Completed
9
Discontinued
PHASE DISTRIBUTIONn = 37
Phase 13Phase 1 / 21Phase 210Phase 2 / 31Phase 313Phase 47Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis

Not yet recruitingPH IVBin Caon=3122026

Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome

Unknown statusPH IVHui Bun=402018

Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil

TerminatedPH IVUniversity of Brasilian=3782015

Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients

CompletedPH IVFundacion SEIMC-GESIDAn=612014

The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients

CompletedPH IVBill McGheen=132010

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis

CompletedPH IIPost Graduate Institute of Medical Education and Research, Chandigarhn=822026

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly: a Randomized Clinical Trial

CompletedPH I/IIHospital Universitário Professor Edgard Santosn=282023

Phase I, Prospective, Randomised, Controlled Study on the Safety and Efficacy of Nebulised Liposomal Amphotericin as an Adjuvant Treatment for Invasive Pulmonary Aspergillosis

CompletedPH IFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajaln=132022

A Randomized Controlled Trial of Combined Inhalational With Intravenous Amphotericin B in Comparison With Intravenous Amphotericin B Alone for Treatment of Pulmonary Mucormycosis

CompletedPH IIPost Graduate Institute of Medical Education and Research, Chandigarhn=302021

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)

CompletedPH IIPoitiers University Hospitaln=1742019

Multi-Center, Open-Label, Randomized, Two Treatment, Parallel, Single Period, Multiple-Dose, Steady State, Global Bioequivalence Study of Amphotericin B Liposome for Injection 50mg /Vial in Patients With Visceral Leishmaniasis

CompletedPH IAurobindo Pharma Ltdn=1402019

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • The Lancet. Infectious diseases1
Leading researchers
  • Bassetti M1
  • Böll B1
  • Brüggemann R1
  • Chakrabarti A1
  • Chen SCA1
  • Colombo AL1
  • Cornely OA1
  • Gangneux JP1
Leading institutions
free-text, unnormalised
  • Center of Expertise in Mycology Radboudumc/CWZ1
  • Centre for Infectious Diseases and Microbiology Laboratory Services1
  • Clinical and Translational Fungal-Working Group and Division of Infectious Diseases and Global Public Health1
  • College of Medicine1
  • Department of Clinical Mycology1
  • Duke University Medical Center1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Amphotericin B

Studied across 3 of the same disease areas as liposomal amphotericin B in the shared literature.

3 shared diseases1 shared paper
Isavuconazole

Studied across 3 of the same disease areas as liposomal amphotericin B in the shared literature.

3 shared diseases1 shared paper
Voriconazole

Studied across 3 of the same disease areas as liposomal amphotericin B in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials